IR-News

AUSSENDER



Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
E-Mail: ir@biofrontera.com

WEITERE IR-NEWS

07.07.2022 - 18:30 | Kontron AG
07.07.2022 - 18:00 | Talenthouse AG
07.07.2022 - 17:50 | Heidelberger Beteiligungsholding AG
pta20220428032
Business news for the stock market

Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to April 29, 2022


Leverkusen, Germany (pta032/28.04.2022/11:35) - Biofrontera AG (ISIN: DE0006046113, US OTC: BFAGY), an international biopharmaceutical company, announces that the publication of the Annual Report will be postponed to Friday, April 29, 2022.

The conference call, in which the Management Board will provide information on key developments in the reporting period, will be rescheduled to Monday, May 2, 2022.

The corresponding dates and dial-in details are listed below.

The conference call for shareholders and interested investors will start at 11:30 a.m. in German and at 2:00 p.m. in English.

Conference Call - GERMAN

May 02, 2022, 11:30 a.m. CEST (5:30 a.m. ET)

Dial-in number: +49 69201744220

Confirmation number: 47974148#

Conference Call - ENGLISH

May 02, 2022, 2:00 p.m. CEST (8:00 a.m. ET)

Dial-in number USA: +1 8774230830

Dial-in number UK: +44 2030092470

Confirmation number: 59031521#

Please dial in as early as 10 minutes prior to the start of the conference call to ensure an on-time start.

-end-

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com

(end)
emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE0006046113 (share)
other stock exchanges: US OTC
|
|
98.695 Abonnenten
|
201.036 Meldungen
|
83.116 Pressefotos

BUSINESS

07.07.2022 - 16:40 | Financial Planning Standards Board Deutschland e.V.
07.07.2022 - 12:20 | SRH AlsterResearch AG
07.07.2022 - 11:55 | SRH AlsterResearch AG
07.07.2022 - 11:45 | pressetext.redaktion
07.07.2022 - 09:30 | DeepSec GmbH
Top